Compare Otis Worldwide Corp (OTIS) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Otis Worldwide Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Otis Worldwide Corp trades at $69.11 (market cap $25.76B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Otis Worldwide Corp is far larger — about 3.4× Spyre Therapeutics Inc. Common Stock's market cap, and Otis Worldwide Corp pays a 2.6% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Otis Worldwide Corp for 66 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| OTIS | SYRE | |
|---|---|---|
Market Cap | $25.76B | $7.52B |
Volume | 6,407,907 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $93.62 | $108.92 |
52-Week Low | $64.05 | $22.18 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $33.80B | $6.52B |
Dividend Yield | 2.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Otis Worldwide trades at $69.11, up 3.54% today but near its 52-week low amid bearish technical signals and recent earnings misses. The company maintains stable revenue around $14.4B with a 10.17% net margin, though service margins face pressure from labor costs. Analyst consensus is mixed with a $87 price target, while institutional investors show varied positioning through recent acquisitions and sales.
The stock presents a defensive opportunity given its dominant elevator service franchise, but near-term upside is limited by margin pressures and China demand uncertainty. Key risks include execution on service margin expansion and macroeconomic headwinds affecting new equipment orders.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
